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Background: Congenital adrenal hyperplasia is a group 
of autosomal recessive disorders caused by a deficiency 
of 1 of 4 enzymes required for the synthesis of glucocor­
ticoids, mineralocorticoids, and sex hormones. Analysis 
of 11-deoxycortisol (11DC), 17-hydroxyprogesterone 
(170HP), 17-hydroxypregnenolone (170HPr), and preg­
nenolone (Pr) in blood allows detection of these enzyme 
defects.
M eth od s: The steroids were extracted from 200 fiL of 
serum or plasma by solid-phase extraction, derivatized 
to form oximes, and extracted again with methyl f-butyl 
ether. Instrumental analysis was performed on an API 
4000 tandem mass spectrometer with electrospray ion­
ization in positive mode and multiple reaction-monitor­
ing acquisition.
R esults: The limits of detection were 0.025 /ug/L for 
11DC, 170HP, and Pr and 0.10 /xg/L for 170HPr. The 
method was linear to 100 jug/L for 11DC, 170HP, and Pr, 
respectively, and to 40 /xg/L for 170HPr. Within- and 
between-run (total) imprecision (CVs) were <7.1% and 
11%, respectively. Reference intervals for children in 
Tanner stages 1 through 5 and adult males and females 
for 170HP, 11DC, Pr, and 170HPr were established. 
Prepared samples were stable for >72 h.
Conclusions: The detection limit and selectivity of this 
method and its small sample volume requirement allow 
analysis of endogenous concentrations of adrenal ste­
roids in serum or plasma from children and adults. The 
method thus has an important potential role in the 
evaluation of the status of 4 of the enzymes involved in 
adrenal steroid biosynthesis.
© 2006 American Association for Clinical Chemistry
Congenital adrenal hyperplasia (CAH)4 is a group of 
autosomal recessive disorders caused by a deficiency of 1 
of 4 enzymes required for the synthesis of glucocorticoids, 
mineralocorticoids, and sex hormones (7-5). CAH may 
present with variety of clinical findings, such as viriliza­
tion of the affected infants, signs of androgen excess, 
salt-wasting crisis secondary to aldosterone deficiency, or 
hormonal hypertension attributable to increased miner­
alocorticoids. The most common type of CAH is 21- 
hydroxylase deficiency, which is the result of sequence 
variations in the cytochrome P450, family 21, subfamily A, 
polypeptide 2 gene (CYP 21A2f also known as CYP21) 
located on chromosome 6. Most of the remaining cases of 
CAH are caused by a deficiency of llZi-hydroxylase, 
17a-hydroxylase, or SMiydroxysteroid dehydrogenase. 
Evaluation of the concentrations of the steroid intermedi­
ates in the cholesterol pathway, i.e., 11-deoxycortisol 
(11DC; Reichstein's substance S), 17-hydroxyprogesterone 
(170HP), 17-hydroxypregnenolone (170HPr), and preg­
nenolone (Pr), allows detection of these enzyme defects 
(6 -9 ). If a person has deficiency of one of the enzymes,
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this leads to accumulation of the steroid precursors prox­
imal to the enzyme defect. Simultaneous analysis of 
multiple steroids involved in the pathway helps in mak­
ing a correct diagnosis because in some cases 170HP can 
be increased in llfr-hydroxylase deficiency. Therefore, the 
enzyme defect can be confused with 21-hydroxylase de­
ficiency if 11 DC is not measured simultaneously.
Testing for adrenal steroids is also useful for differen­
tial diagnosis of polycystic ovary syndrome and nonclas­
sic forms of CAH, which may sometimes be indistinguish­
able by clinical presentation and sonography (6).
To date, determination of 11DC, Pr, and 170HPr is 
based solely on immunoassays and gas chromatography- 
mass spectrometry (GC-MS), which are available only in a 
few clinical laboratories (10-14). The accuracy of immu­
noassays varies significantly because of cross-reactivity 
and matrix effects, immunoassays can have poor negative 
and positive predictive values, especially in preterm and 
acutely ill neonates (15-17). Because interfering sub­
stances and the degree of interference vary among com­
mercially available immunoassays, reference intervals for 
adrenal steroids are often method-specific and cannot be 
used interchangeably (18-23).
Several GC-MS methods have been developed for 
measurement of adrenal steroids. These methods have 
good specificity, but they usually have low throughput 
and require large sample volumes (24,25). The majority 
of the published tandem mass spectrometry (MS/MS) 
methods for measurement of adrenal steroids allow mea­
surement of concentrations characteristic of pathologic 
conditions but are not sensitive enough to measure phys­
iologic endogenous concentrations (26-32). Lacey et al.
(32) developed a liquid chromatography (LQ-M S/M S 
method for steroid profiling of newborns from dried 
blood spots collected on filter paper. Through measure­
ment of 170HP, androstenedione, and cortisol, the 
method allows evaluation of the status of the enzymes 
involved in the pathway and thus provides a better tool 
for diagnosis of CAH than does measurement of 170HP 
alone.
We have developed a sensitive and specific LC- 
MS/MS assay for simultaneous measurement of endoge­
nous concentrations of adrenal steroids that uses a small 
sample volume and allows evaluation of status of 4 of the 
enzymes involved in adrenal steroid biosynthesis. For the 
first time, reference intervals for males and females of 




We purchased 11DC, 170HP, 170HPr,and Pr (all purities 
>98%) from Sigma. Deuterated analogs of the steroids 
(HDC-d2, 170HP-d8, 170HPr-d3, and Pr-d4) were pur­
chased from Cambridge Isotope Laboratories. Stock solu­
tions of 11 DC, 170HP, and Pr were prepared in methanol, 
and 170HPr was prepared in ethanol at a concentration of
1 g /L . Working combined calibrators and internal stan­
dards were prepared in an equivolume mixture of water 
and methanol at concentrations of 10 and 20 /mg/L, 
respectively. Adrenal steroid calibrators were prepared in
10 g /L  bovine serum albumin at concentrations of 0.5, 1, 
2.5, and 5.0 /mg/Lb (50,100, 250, 500 ng/dL) with each set 
of samples. HPLC-grade water, methanol, methyl f-butyl 
ether (MTBE), and acetonitrile were obtained from Fisher 
Scientific. All other reagents were obtained from Sigma. 
Strata X ,M solid-phase extraction (SPE) columns were 
purchased from Phenomenex.
SAMPLE PREPARATION
Aliquots (200 /mL) of calibrators, controls, or patient serum 
were transferred into glass tubes containing 2 mL of 
water. To each of these, we added 20 /mL of a working 
combined internal standard. The samples were extracted 
with SPE as follows: columns were preconditioned by 
consecutive addition of 2 mL of methanol and water; 
samples were applied and drained by gravity; columns 
were washed with 3 mL of water followed by 3 mL of 200 
m L/L acetonitrile in water, and then dried for 15 min; 
finally, steroids were eluted with 3 mL of MTBE. The 
solvent was evaporated under nitrogen in a 35 °C water 
bath, and the dried residue was redissolved for derivati- 
zation in 300 /mL of an aqueous hydroxylamine solution 
(1.5 m ol/L , pH 10). The tubes were vortex-mixed and 
incubated in a heating block at 90 °C for 30 min, and the 
derivatives were extracted with 2 mL of MTBE. The 
solvent was evaporated, the residue was reconstituted 
with 75 /mL of methanol-water (2:1 by volume), and the 
samples were analyzed on the LC /M S/M S instrument.
lc-m s / ms
The method was validated on an API 4000 triple-quadru- 
pole mass spectrometer (Applied Biosystems/MDS Sciex) 
equipped with a V spray ionization source operated at 
400 °C. The system included an Agilent HPLC pump and 
oven (Series 1100) and a Perkin-Elmer 200 Series autosam­
pler. The chromatographic separation was performed on a 
Phenomenex Synergy Fusion,M RP (C18) column [50 X 2.0 
mm (i.d.); particle size, 4 /mm]. The injection volume was 
15 /mL, and the oven temperature was 50 °C. Mobile phase 
A was methanol, mobile phase B was 22 m m ol/L  aqueous 
formic acid. Mobile phase was delivered at a flow rate of
0.5 m L/min with the following program: 60% methanol 
for 2 min, linear gradient to 75% methanol between 2 and
3.5 min, step gradient to 97% of methanol at 6 min, 
followed by reequilibration to initial conditions between 
6.4 and 7.2 min. The autosampler injection syringe was 
washed between the injections 12 times with methanol-
6 Throughout the manuscript, steroid concentrations are expressed in 
/xg/L; the conversion factors to nmol/L are 2.888, 3.028, 3.010, and 3.162 for 
11-deoxy cortisol, 17-hydroxyprogesterone, 17-hydroxypregnenolone, and 
pregnenolone, respectively.
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water (4:1 by volume) containing 8.8 m m ol/L  trifluoro- 
acetic acid. The Q1 and Q3 quadrupoles were tuned for 
unit resolution, and the mass spectrometer conditions 
were optimized for maximum signal intensity of each 
adrenal steroid. The instrument was operated in positive- 
ion mode with an ion spray voltage of 4000 V and 
entrance potential of 10 V. MS/MS transitions used for the 
adrenal steroids and their internal standards and com­
pound-specific voltages are listed in Table 1. Nitrogen 
was used as the gas in the collision cell. All data were 
acquired and processed with Analyst,M 1.4.1 software 
(Applied Biosystems/MDS Sciex). Quantitative calibra­
tion was performed with every batch of samples and was 
used in conjunction with the intensities of the transitions 
of internal standards to calculate concentrations in un­
known samples. An API 3000 (Applied Biosystems/MDS 
Sciex) triple-quadrupole mass spectrometer was used to 
study relative sensitivities among different ion sources 
and for initial evaluation of the method.
ASSAY PERFORMANCE CHARACTERISTICS 
We determined the method imprecision by analyzing 3 
replicates per run of samples containing adrenal steroids 
at concentrations of 0.8, 4.6, 9.0, and 18.0 p,g /L  in 1 run 
per day over a 5-day period. The samples were prepared 
in 10 g /L  bovine serum albumin, aliquoted, and stored at 
—70 °C until analysis. We evaluated method linearity by 
analyzing samples prepared with adrenal steroid concen­
trations between 1 and 100 p,g /L . We determined method 
sensitivity by analyzing samples prepared by serial 2-fold 
dilutions a sample containing 1.0 p,g /L  adrenal steroids; 
the lowest evaluated concentration was 0.01 p,g /L . To 
determine the upper limit of linearity and limit of quan-
Table 1. Multiple-reaction monitoring transitions monitored 
(m/z) and compound-specific settings.
Compound Mass transition, m/z DP,” V CE, V
11 DC 377.2^*124.1 60 42
377.2^112.1 60 42
HDC-d2 379.2^124.1 60 42
379.2^112.1 60 42
ITOHPr 348.2^330.2 35 5
348.2^312.2 35 20
348.2^330.2 35 3
170HPr-d3 351.2^333.2 35 5
351.2^*315.2 35 20
351.2^333.2 35 3
170HP 361.2^124.1 60 45
361.2^112.1 60 45
170HP-d8 369.2^128.1 60 45
369.2^115.1 60 45
Pr 332.2^86.0 60 40
332.2^300.2 60 30
Pr-d4 336.2^90.0 60 40
336.2^304.2 60 30
a DP, declustering potential; CE, collision energy.
tification for the assay, we used the following criteria: 
imprecision (CV) <20%; a branching ratio of the mass 
transitions within 30% of the value set by the calibration; 
and measured values within 30% of the expected values. 
The limit of detection was defined as the lowest concen­
tration at which chromatographic peaks of the adrenal 
steroids were present in both transitions at expected 
retention times. We determined the recovery by analyzing 
a patient sample containing 0.50-1.50 p,g /L  endogenous 
adrenal steroids to which we added 0.50 p,g /L  each of
11 DC, 170HP, 170HPr, and Pr. We compared the ob­
served differences in the concentrations after the addi­
tions with the added concentrations. We determined the 
extraction efficiency of SPE by analyzing sample with 
combined internal standard added before and after SPE 
and comparing the observed concentrations.
To determine cross-reactivity, we analyzed 43 steroids, 
steroid metabolites (see Table 1 in the Data Supplement 
that accompanies the online version of this article at 
http://w w w .clinchem .org/content/vol52/issue8/), and 
>2000 random patient samples. A branching ratio of the 
transitions outside of established limits, broadening of the 
chromatographic peaks, split peaks, or an increase in the 
background were interpreted as potential interference.
We evaluated ion suppression by analyzing extracted 
samples with adrenal steroid concentrations <1.00 p,g /L  
injected in a flow of derivatized adrenal steroids prepared 
at a concentration of 0.50 ^-g/L, infused by syringe at a 
flow rate of 10 ^,L/min. A decrease in the intensity of the 
baseline in the mass transitions of the adrenal steroids 
was considered evidence of ion suppression.
REFERENCE INTERVALS AND SPECIMEN-TYPE 
SUITABILITY AND STABILITY
We collected serum samples for the reference interval 
study from apparently healthy volunteers after obtaining 
informed consent. Women on oral contraceptives or hor­
mone replacement therapy were excluded from the study. 
Samples from children of Tanner stages 1 through 5 were 
collected after receipt of parental informed consent. The 
mean (median) ages of the adult volunteers were 32 (31.2),
52.5 (52), and 28.5 (37.5) years for premenopausal females, 
postmenopausal females, and males, respectively. The 
samples were stored at —70 °C and thawed once before 
the analysis.
The stability of the steroids under different storage 
conditions was evaluated. Portions of serum samples 
containing 0.90-1.20 p,g /L  11 DC, 170HP, 170HPr, and Pr 
were stored at room temperature, at refrigerator temper­
ature (4 °C), and in a freezer (—20 °C). The samples were 
transferred into a —70 °C freezer after 1,3,7,14,21, and 30 
days of storage and analyzed in a single batch. Blood from 
a volunteer was collected in a serum gel separator tube, a 
sodium EDTA tube, and a sodium heparin tube for 
assessment of specimen-type suitability. All studies with 
samples from human participants were approved by 
Institutional Review Board of the University of Utah.
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Fig. 1. Multiple-reaction monitoring chromatograms of extracted patient serum samples containing 0.21 /ig/L 11DC (A), 0.65 /ig/L 170HPr (B), 
0.19 /ig/L 170HP (C), and 0.38 fig/L Pr (0).
Mass transitions (solid line, primary mass transition: dashed line, secondary mass transition): A, m/z 377.2^124.1 and 377^112: B, m/z 348^330 and 348^312: 
C, m/z 361^124 and 361-»112; D, m/z 332^86 and 332^300.
METHOD COMPARISON
We compared the LC-MS/MS method with an RIA for 
170HP (n = 87; Coat-a-count; Diagnostic Products Cor­
poration) and an LC-MS/MS method (n = 10) of a 
commercial laboratory. Method comparisons for Pr (n = 
58), 170HPr (n = 35), and 11 DC (n = 10) were performed 
with RIA methods of a commercial laboratory. To account 
for imprecision in both the comparison and the evaluated 
methods, the results were analyzed by Deming regression.
Results
The ionization efficiency of nonderivatized adrenal ste­
roids was studied in positive and negative ion modes
with mobile phase containing various solvents and buff­
ers and by use of electrospray ionization (ESI), heated 
nebulizer [atmospheric pressure chemical ionization 
(APCI)], and atmospheric pressure photoionization ion 
sources on an API3000 (Applied Biosystems/MDS Sciex) 
tandem mass spectrometer. Samples containing 10 joig/L 
each of 11 DC, 170HP, 170HPr, and Pr were injected in a 
flow of mobile phase (flow rate, 250 /mL/min).
The absolute intensity of the [M + H]+ molecular ion of 
170HP was highest with atmospheric pressure photoion­
ization (toluene was used as a dopant) followed by APCI 
and ESI. The [M + H]+ molecular ion of 170HP was 
observed with each ionization method, whereas Pr and
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170HPr were not detectable with any ionization tech­
nique, and the sensitivity (that is, the change in signal for 
a change in analyte) for 11DC was approximately one 
third that of 170HP.
The poor ionization efficiency and collision-induced 
dissociation (CID) fragmentation of 11DC, 170HPr, and 
Pr led us to evaluate the effect of derivatization on the 
sensitivity of MS/MS detection. The most promising 
derivatization of those evaluated was the oximation reac­
tion, with hydroxylamine reacting with keto groups of the 
steroids to form oxime derivatives. Comparison of the 
signal intensity for nonderivatized steroids and the oxime 
derivatives in positive ion mode showed the best sensi­
tivity with ESI. We found that ionization was more 
efficient with addition of formic acid to the mobile phase 
compared with the formate buffer (see Fig. 1 in the online 
Data Supplement). This was especially true for 170HPr 
and Pr. The intensity of the molecular ion of 170HPr 
oxime was also highly dependent on the declustering 
potential and the temperature in the ion source.
The chromatograms of 2 multiple-reaction monitoring 
transitions for each compound in human serum are pre­
sented in Fig. 1. Total ion chromatograms of a sample 
from a healthy female patient and females with suspected 
21-hydroxylase and 3£>-hydroxysteroid dehydrogenase 
deficiencies are shown in Fig. 2 of the online Data Sup­
plement.
Experiments evaluating the ion suppression showed a 
decrease in the baseline at a retention time of 0.5 min, 
baseline recovery by 0.65 min, and no ion suppression at 
the retention times of the adrenal steroids (see Fig. 3 in the 
online Data Supplement).
Concentrations of the steroids were determined by use 
of the first listed mass transition for each compound and 
its internal standard (Table 1). Additional mass transitions 
(listed second for each of the steroid and its internal 
standard) were used to assess the specificity of the detec­
tion. The calibrator containing 1.00 ju.g/L each of the 
adrenal steroids was used to set a threshold for the 
branching ratio of the mass transitions for a batch of 
samples. The acceptance limit for the branching ratio was 
set at 30% for 11 DC, 170HP, and Pr and at 40% for 
170HPr when compared with the branching ratio set by 
the calibrators.
Method performance characteristics are listed in Table
2, and the within-run, between-run, and total imprecision 
and recovery data obtained are shown in Table 2 of the 
online Data Supplement. The results of the method com­
parison are presented in Fig. 2.
The branching ratios of the 2 mass transitions for 11 DC, 
170HP, and Pr in all patient samples were within the 
acceptance limits. The branching ratio for 170HPr was 
outside of the 40% limits in —5% of samples from adults 
and up to 30% of samples from children. For the above 
samples, an alternative mass transition (Table 1) was used 
for evaluation of the selectivity. Additional mass transi­
tions were the same as the primary (in/.z 348^330 for
170HPr and in/.z 351^333 for 170HPr-d3) but were 
acquired at a collision energy 40% lower than the primary 
mass transitions.
Steroids and metabolites of steroids (see Table 1 in the 
online Data Supplement) were evaluated for potential 
interference with the method. The steroids were analyzed 
at a concentration of 100 /u.g/L, and the chromatograms 
were evaluated for the presence of peaks at the mass 
transitions used in the method. None of the evaluated 
steroids interfered with the method.
Under the various storage conditions, 11DC and 
170HP were stable, but 170HPr and Pr were not (see Fig.
4 in the online Data Supplement). No degradation of the 
steroids was observed after 3 freeze/thaw cycles.
We observed no significant differences in analyte re­
covery for serum, EDTA plasma, or heparin plasma for
11 DC, 170HPr, and 170HP, but the Pr concentration in 
the sample collected in sodium EDTA was 280% higher 
than the concentrations in serum and sodium-heparin 
plasma. Collection tubes containing EDTA should there­
fore not be used. The adrenal steroids appeared to be 
stable during 3 months of storage at —20 °C.
Results of analysis of the samples from volunteers 
grouped by Tanner stages and age are summarized in 
Tables 3 and 4. The main differences in the results 
grouped by Tanner stage between males and females 
were in the Pr concentration at Tanner stage 2, which 
was ~  60% higher in females; 170HP at Tanner stages 2 
and 3, which was —30% higher in females; and 11DC at 
Tanner stage 4 -5 , which was —40% higher in males than 
in females. In adult females (Table 4), 170HPr concentra­
tions were 50% lower and 170HP concentrations were 
—30% higher than in males.
Discussion
Despite structural similarities among adrenal steroids, the 
efficiencies of soft ionization methods (ESI and APCI) for 
their detection were very different. To date there have
Table 2. Summary of the method performance 
characteristics.
11DC 170HP 170HPr Pr
S/Na ratio 51 12.6 8.5 69
Recovery,* % 91.0 97.2 99.3 96.5
Absolute recovery 89 100 98 100
of SPE,C %
L0D,d fxg/L 0.025 0.025 0.10 0.025
LOQ, fxg/L 0.05 0.05 0.25 0.05
Upper limit of 100 100 40 100
linearity, fxg/L
a S/N, signal-to-noise ratio. Sample contained 0.50 /ng/L each of the adrenal 
steroids, and 20 pg was injected in HPLC column (n = 5).
6 Determined by analyzing serum samples with and without addition of 0.50 
jug/L each of the steroids (n = 2).
° Determined by analyzing serum samples with internal standard added before 
and after SPE (n = 2). 
a LOD, limit of detection; LOQ. limit of quantification.
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Fig. 2. Comparison of the evaluated method with RIAs (A-D) and LC-MS/MS (C) methods of commercial laboratories for 11DC (A), ITOHPr (B), 
1TOHP (C), and Pr ID).
Regression statistics: (A), y = 1.41X + 0.08 /ug/L (r— 0.985: Sy„ = 0.09 /ug/L); (B), y = 1 .07x- 0.09 /ug/L (r— 0.955: Sy„ = 0.76 /ug/L); (C), for RIA (A), y = 1.76x 
+ 0.42 (ig/L (r = 0.986: Syx = 0.95 jag/L): for LC-MS/MS (153), y = l.Olx -  0.009 jag/L (r = 1.00: Sy„ = 0.14 jag/L): (0), y = 0.47x + 0.48 jag/L (r = 0.310: Sy„ 
= 0.54 ,ug/L).
been no published LC-MS methods for quantification of 
endogenous concentrations of 170HPr and Pr. This is 
most likely related to poor ionizability of the molecules 
caused by the position of the double bond within the 
structure. In 11 DC and 170HP, the double bond is located 
in ring A, whereas in Pr and 170HPr it is located in ring
B. The steroids included in the method contain 1 (170HPr 
and Pr) and 2 (11 DC and 170HP) keto groups within the 
structure, which if derivatized may enhance detection
(33). Improvements in sensitivity of detection of adrenal 
steroids were achieved through formation of oxime de­
rivatives and optimization of the sample preparation and 
ionization. Formation of the double oxime derivatives of 
11DC and 170HPr requires more stringent conditions 
(higher temperature and longer incubation time) than 
does formation of derivatives of 170HP and Pr (results 
not presented).
The greatest intensities of the molecular ions among
the evaluated ionization techniques were for oxime deriv­
atives of adrenal steroids with an ESI ion source and a 
mobile phase consisting of methanol and 0.022 m ol/L  
formic acid (see Fig. 1 in the online Data Supplement). The 
oxime derivatives of adrenal steroids were efficiently 
ionized at relatively low voltage. Under these conditions, 
most other compounds present in serum would not be 
well ionized, giving greater specificity. The ease of ion­
ization of the oxime derivatives can be explained by the 
presence of the resonance structures (34) promoted by the 
delocalization of charge within the molecule (see Scheme
1 in the online Data Supplement). In the oxime group, the 
nitrogen atom is bound to a carbon by a double bond. The 
angle between the nitrogen and the hydroxyl group is 
—120 degrees; this leads to the formation of isomers that 
differ by the orientation of the —OH group. Structures b 
and c (see Scheme 1 in the online Data Supplement) allow 
free rotation along the carbon-nitrogen bond, whereas the
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Table 3. Reference intervals (jig/L) for 11DC, 170HP, 
170HPr, and Pr by Tanner stage.®
n 11DC 170HPr 170HP Pr
Females
Tanner 1 181 <0.93 <2.35 <0.74 0.15-1.53
Tanner 2 76 <1.36 <3.67 <1.64 0.22-2.29
Tanner 3 98 <0.97 <4.30 0.12-2.09 0.34-2.15
Tanner 4-5 104 <0.49 0.26-4.12 0.07-1.70 0.26-2.35
Males
Tanner 1 171 <1.05 <2.08 <0.62 0.13-1.55
Tanner 2 80 <1.06 <3.55 <1.04 0.12-1.43
Tanner 3 83 <1.11 <4.50 <1.51 0.16-2.14
Tanner 4-5 122 <0.81 0.35-4.78 0.20-1.73 0.19-2.01
a Results are the nonparametric estimates of the central 95% interval.
rotation between the atoms is restricted in structures a 
and d. We confirmed the presence of isomers by resolving 
the isomers of the analogous testosterone oxime with 
high-field asymmetric wave ion mobility LC-FAIMS- 
MS/M S (35).'
In the adrenal steroid biosynthesis pathway, Pr is 
produced directly from cholesterol and is the precursor 
for all C18, C19, and C21 steroids. A  large portion of Pr is 
present in blood in a conjugated form. All evaluated types 
of extraction other than direct SPE with samples at 
physiologic pH caused partial hydrolysis of Pr conjugates 
with consequent increases in the concentration of conju­
gated Pr compared with the concentration of unconju­
gated Pr.
Chromatographic separation plays an important role in 
method performance. The Synergy Fusion column (C18 
with imbedded polar end-capping) provided sufficient 
retention and separation of the oxime derivatives of 
adrenal steroids and did not cause peak splitting for any 
of the steroids except for partial resolution of the 170HP- 
oxime diastereomers.
Table 4. Reference intervals (jig/L) for 11DC, 170HP, 
170HPr, and Pr by age.3
Age, years n 11DC 170HPr 170HP Pr
Females
7-9 126 <0.93 <2.12 <0.71 0.14-1.50
10-11 83 <1.06 <3.20 <0.89 0.15-1.97
12-13 84 <1.34 <3.62 <1.65 0.22-2.20
14-15 83 <1.05 0.28-4.22 0.12-2.08 0.23-2.14
16-17 83 <0.47 0.25-4.19 <1.79 0.22-2.29
18-51* 56 <0.41 <2.08 0.10-1.98 0.17-1.30
Males
7-9 126 <1.18 <1.87 <0.63 0.13-2.05
10-11 83 <1.06 <3.87 <0.70 0.12-1.51
12-13 83 <0.93 <3.62 <1.05 0.18-1.70
14-15 84 <0.92 0.32-4.28 <1.52 0.17-1.98
16-17 84 <1.05 0.31-4.78 <1.93 0.16-2.29
18-52 44 <0.50 0.36-4.09 0.25-1.39 0.28-1.65
a Results are the nonparametric estimates of the central 95% interval. 
6 Premenopausal.
To assess selectivity of the analysis in MS/MS, it is 
advantageous to use multiple mass transitions for the 
analytes of interest (34 ,3 6 -39). The CID mass spectra of 
11DC, 170HP, and Pr contained 2 unique product ions 
originating from loss of large fragments of the molecule, 
whereas the CID mass spectrum of 170HPr was not as 
specific and the only major product ions in the mass 
spectrum resulted from the loss of 1 and 2 molecules of 
water. To enhance the selectivity, we evaluated a 2-stage 
fragmentation M S/M S/M S by use of the ion trap function 
of the API4000 mass spectrometer with the parent ion (m/z 
348), intermediate product ion (m/z 330), and the final 
product ion (m/z 312). M S/M S/M S provided slightly 
better specificity and greater signal intensity; however, 
measurement imprecision increased by more than 3-fold. 
Consequently, for the analysis of 170HPr, we used 
MS/MS fragmentation with the mass transitions m/z 
348^330 and m/z 348^312. The method used 2 mass 
transitions for each adrenal steroid and branching ratios, 
which were calculated from the transitions, and enabled 
evaluation of the specificity of the analysis in every 
sample (36).
Evaluation of sample stability during storage at differ­
ent conditions showed rapid degradation of 170HPr and 
Pr (see Fig. 4 in the online Data Supplement) at refriger­
ator temperatures and, especially, at ambient conditions. 
This suggests that samples for analysis of 170HPr and Pr 
should be frozen immediately after collection and remain 
frozen until analysis. All of the steroids were stable when 
the samples were stored at —20 °C or below.
Method comparisons with RIA for 170HPr and LC- 
MS/MS for 170HP indicated good agreement between 
the methods (Fig. 2). Comparison with RIA for 11DC and 
170HP showed good correlation but produced 41% and 
76% overestimation of the concentrations, respectively, by 
the RIAs. Poor correlation was observed for the compar­
ison with RIA for Pr. Calibrators used in the LC-MS/MS 
method were added to adrenal-steroid-free matrix and 
analyzed by the RIAs. The results showed good agree­
ment with the expected values. This suggests that discrep­
ancies between the methods are related to matrix effects 
and cross-reactivities in the RIAs (15-17).
In summary, we have developed a highly sensitive and 
specific LC-MS/MS method for measurement of 11DC, 
170HP, 170HPr, and Pr in serum or plasma. This method 
allows measurement of endogenous concentrations of 
adrenal steroids in all age groups of females and males. 
Measurements of adrenal steroids by LC-MS/MS are 
precise, and the method has low limits of quantification. 
With an instrumental analysis time of 7 min, the assay is 
a good alternative to immunoassays. We found no inter­
ferences among the compounds tested. Sample prepara­
tion is specific to neutral molecules containing keto 
groups. Compared with GC-MS methods for adrenal 
steroid analysis, the LC-MS/MS method offers better 
selectivity and limits of detection and quantification,
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along with higher throughput and reduced sample vol­
ume requirements. The small sample volume makes the 
method particularly useful for pediatric testing. For the 
first time, reference intervals for 11DC, 170HPr, and Pr 
for males and females of different Tanner stages and age 
groups were established by an isotope-dilution LC- 
MS/MS method.
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